Free Trial

Compare Stocks

→ My top 100 stocks… (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
$33.57
+0.2%		$33.53
$25.07
▼
$34.61
$2.69M1.03467 shs113 shs
STLV
iShares Factors US Value Style ETF
$25.68
$25.67
$0.00
▼
$0.00
$2.57M0.97N/A29 shs
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
$25.61
$25.60
$20.38
▼
$26.36
$2.56M-1.521,191 shsN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
$7.38
$7.38
$5.87
▼
$11.83
$2.21M0.923,034 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
0.00%+1.78%-3.00%+10.93%+32.52%
STLV
iShares Factors US Value Style ETF
0.00%0.00%0.00%0.00%-3.20%
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
0.00%0.00%0.00%-0.39%+2,560,999,900.00%
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
0.00%0.00%0.00%0.00%-16.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
N/AN/AN/AN/AN/AN/AN/AN/A
STLV
iShares Factors US Value Style ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
0.00
N/A$37.5711.92% Upside
STLV
iShares Factors US Value Style ETF
0.00
N/A$28.2610.08% Upside
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
0.00
N/A$30.0417.29% Upside
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
0.00
N/A$25.09240.00% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
N/AN/AN/AN/AN/AN/A
STLV
iShares Factors US Value Style ETF
N/AN/AN/AN/AN/AN/A
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
N/AN/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
N/AN/A23.61∞N/AN/AN/AN/AN/A
STLV
iShares Factors US Value Style ETF
N/AN/A9.06∞N/AN/AN/AN/AN/A
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
N/A-$2.08N/A∞N/AN/AN/AN/AN/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/A0.00∞N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
$0.190.57%N/AN/AN/A
STLV
iShares Factors US Value Style ETF
N/AN/AN/AN/AN/A
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
$1.636.36%N/AN/A N/A
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/AN/AN/AN/AN/A

Latest STLV, FIXT, VR, and XDNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/25/2024
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
$0.09793/26/20243/27/20243/28/2024
(Data available from 1/1/2013 forward)

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
N/A
STLV
iShares Factors US Value Style ETF
N/A
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
81.98%
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A

Insider Ownership

CompanyInsider Ownership
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
N/A
STLV
iShares Factors US Value Style ETF
N/A
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
2.33%
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Procure Disaster Recovery Strategy ETF stock logo
FIXT
Procure Disaster Recovery Strategy ETF
N/A80,000N/ANot Optionable
STLV
iShares Factors US Value Style ETF
147,000100,000N/ANot Optionable
Global X Metaverse ETF stock logo
VR
Global X Metaverse ETF
N/A100,000N/AOptionable
Kelly CRISPR & Gene Editing Technology ETF stock logo
XDNA
Kelly CRISPR & Gene Editing Technology ETF
N/A300,000N/AOptionable

STLV, FIXT, VR, and XDNA Headlines

SourceHeadline
CRISPR gene editing: in summaryCRISPR gene editing: in summary
biotechniques.com - March 27 at 7:54 AM
CRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeCRISPR Technology Takes Center Stage at SXSW 2024 for the First Time
markets.businessinsider.com - March 9 at 12:31 AM
Intellia Collaborates With ReCode To Develop Gene Therapy For Cystic FibrosisIntellia Collaborates With ReCode To Develop Gene Therapy For Cystic Fibrosis
markets.businessinsider.com - February 15 at 1:13 PM
CRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching ImplicationsCRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching Implications
techbullion.com - January 18 at 4:05 PM
Heres Why CRISPR Therapeutics Stock Rose 54% Last YearHere's Why CRISPR Therapeutics Stock Rose 54% Last Year
msn.com - January 15 at 6:44 PM
Gene editing is now a medical realityGene editing is now a medical reality
news.yahoo.com - December 8 at 6:57 PM
FDA approves first use of CRISPR gene editing to treat sickle cell diseaseFDA approves first use of CRISPR gene editing to treat sickle cell disease
news.yahoo.com - December 8 at 1:57 PM
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood DisorderFDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
markets.businessinsider.com - December 8 at 1:57 PM
Gene Editing Will Change Medicine—and Maybe Health Investing TooGene Editing Will Change Medicine—and Maybe Health Investing Too
msn.com - November 24 at 7:36 AM
CRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breedingCRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breeding
phys.org - November 24 at 12:55 AM
Is CRISPR Therapeutics the Best Gene-Editing Stock?Is CRISPR Therapeutics the Best Gene-Editing Stock?
msn.com - November 22 at 8:20 AM
Three people were gene-edited in an effort to cure their HIV. The result is unknown.Three people were gene-edited in an effort to cure their HIV. The result is unknown.
technologyreview.com - November 16 at 1:27 AM
3 Biotech Stocks That Are Betting on the Future of Gene Editing3 Biotech Stocks That Are Betting on the Future of Gene Editing
markets.businessinsider.com - November 9 at 4:19 PM
CRISPR gene editing could kill HIV. But is it a cure?CRISPR gene editing could kill HIV. But is it a cure?
msn.com - October 30 at 5:29 PM
CRISPR Virtual Event Series 2023CRISPR Virtual Event Series 2023
labroots.com - October 29 at 7:51 PM
Researcher discusses CRISPR-Cas3 as a DNA shredder for gene therapyResearcher discusses CRISPR-Cas3 as a DNA shredder for gene therapy
phys.org - October 29 at 7:51 PM
Cantor Fitzgerald Downgrades CRISPR Therapeutics (CRSP)Cantor Fitzgerald Downgrades CRISPR Therapeutics (CRSP)
msn.com - October 17 at 11:13 PM
CRISPR Gene Editing: Changing the Future of ScienceCRISPR Gene Editing: Changing the Future of Science
bates.edu - October 3 at 8:56 PM
CRISPR and Genome Editing – News and FeaturesCRISPR and Genome Editing – News and Features
technologynetworks.com - August 18 at 3:25 AM
CRISPR and Genome EditingCRISPR and Genome Editing
technologynetworks.com - August 17 at 8:45 AM
CRISPR Market is Expected to Reach $7.1 Billion | MarketsandMarkets.CRISPR Market is Expected to Reach $7.1 Billion | MarketsandMarkets.
finance.yahoo.com - August 3 at 11:42 PM
Gene Editing Market worth $10.6 billion | MarketsandMarketsGene Editing Market worth $10.6 billion | MarketsandMarkets
benzinga.com - July 16 at 6:50 PM
Improvement to CRISPR gene editing could make it more effectiveImprovement to CRISPR gene editing could make it more effective
sciencedaily.com - July 8 at 5:31 PM
CRISPR Therapeutics: A Galaxys Worth of Deep ValueCRISPR Therapeutics: A Galaxy's Worth of Deep Value
msn.com - May 31 at 8:24 AM

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Procure Disaster Recovery Strategy ETF logo

Procure Disaster Recovery Strategy ETF

NASDAQ:FIXT
The Procure Disaster Recovery Strategy ETF (FIXT) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks an equal-weighted index of globally listed companies that aid in natural disaster recovery strategies. The index comprises four investment categories: climatological, geophysical, hydrological, and meteorological. FIXT was launched on Jun 1, 2022 and is managed by ProcureAM.

iShares Factors US Value Style ETF

BATS:STLV
The iShares Factors US Value Style ETF (STLV) is an exchange-traded fund that mostly invests in large cap equity. The fund tracks an index of US large and mid-cap value stocks selected based on a combination of five investment factors. STLV was launched on Jan 14, 2020 and is managed by BlackRock.
Global X Metaverse ETF logo

Global X Metaverse ETF

NASDAQ:VR
The Global X Metaverse ETF (VR) is an exchange-traded fund that is based on the Global X Metaverse index. The fund tracks a market cap-weighted index of 40 global companies that derive revenue from or have primary business operations associated with the Metaverse. VR was launched on Apr 26, 2022 and is managed by Global X.
Kelly CRISPR & Gene Editing Technology ETF logo

Kelly CRISPR & Gene Editing Technology ETF

NASDAQ:XDNA
The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.